Document Detail


Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
MedLine Citation:
PMID:  1717094     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In a multi-centre study strontium-89 was shown to be effective in relieving bone pain from prostatic carcinoma in patients who had failed conventional therapies. Of 83 patients assessed at 3 months, following the administration of a dose of at least 1.5 MBq/kg, 75% derived benefit and 22% became pain free. Symptomatic improvement usually occurred within 6 weeks and continued for between 4 and 15 months (mean 6 months). Based on the dose estimation part of this study the recommended dose of strontium-89 is 150 MBq. Toxicity was low, provided platelet levels were above 100 x 10(9) l-1 at the time of treatment. Repeat treatments with strontium-89 may be given at intervals of not less than 3 months. Strontium-89 is administered intravenously on an out-patient basis with no special radiological protection precautions.
Authors:
A H Laing; D M Ackery; R J Bayly; R B Buchanan; V J Lewington; A J McEwan; P M Macleod; M A Zivanovic
Related Documents :
1379924 - First canadian clinical study of transurethral hyperthermia in benign prostatic hyperpl...
9256324 - Influence of prostate size on terazosin efficacy.
8365444 - Quality of life after radical retropubic prostatectomy for carcinoma of the prostate.
10654894 - Pretreatment prostate-specific antigen as an outcome predictor of targeted transurethra...
11547294 - Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in ...
21282754 - Short- and long-term mortality following primary total hip replacement for osteoarthrit...
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  The British journal of radiology     Volume:  64     ISSN:  0007-1285     ISO Abbreviation:  Br J Radiol     Publication Date:  1991 Sep 
Date Detail:
Created Date:  1991-11-14     Completed Date:  1991-11-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0373125     Medline TA:  Br J Radiol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  816-22     Citation Subset:  AIM; IM    
Affiliation:
Department of Radiotherapy, Churchill Hospital, Oxford, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Neoplasms / pathology,  radiotherapy,  secondary*
Humans
Male
Palliative Care / methods*
Platelet Count / radiation effects
Prostatic Neoplasms / pathology*
Radiotherapy Dosage
Strontium / therapeutic use*
Strontium Radioisotopes / therapeutic use
Chemical
Reg. No./Substance:
0/Strontium Radioisotopes; 10476-85-4/strontium chloride; 7440-24-6/Strontium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Modulation of gastric contractions in response to tachykinins and bethanechol by extrinsic nerves.
Next Document:  Cytokeratin shedding in urine as a biological marker for bladder cancer: monoclonal antibody-based e...